Price promise. We match any EU-based offer on the same peptide and specification.

Industry brief · Română

Peptide News

A dated log of research and industry stories — trials, regulators, supply, and literature. Newest week first. Open a month, then a week.

Research context only. These notes are not protocols, not product claims for SiAna vials, and not medical advice. Research use only — not for human or animal use.

November 2026
Week of 16 Nov 2026

PRI-002: oral all-D-peptide misses primary endpoint in Phase 2 Alzheimer's trial but shows later cognitive signals

Priavoid reported on November 17, 2026, at the CTAD conference, topline results from the randomized, double-blind, placebo-controlled Phase 2 PRImus-AD trial of PRI-002, an oral all-D-peptide designed to break up toxic amyloid-beta oligomers, in 304 people aged 55–80 with mild cognitive impairment or mild dementia due to Alzheimer's disease. The trial met its primary safety endpoint but missed its primary efficacy endpoint (change in CDR-SB at week 48); in exploratory week-72 analyses, decline on the ADAS-Cog13 cognitive scale was 26.7% slower than placebo in the main analysis (p=0.102) and 35.9% slower in the per-protocol population (p=0.022). Brain microbleeds (ARIA-H) were reported in 8% and 11.7% of the two dose groups versus 5% on placebo. The results are company-reported and not yet peer-reviewed, the significant finding comes from an exploratory per-protocol analysis, and the full dataset is expected in 2027.

Priavoid press release · ClinicalTrials.gov record

Galinpepimut-S: WT1 peptide vaccine meets overall survival endpoint in Phase 3 REGAL trial in acute myeloid leukemia

SELLAS Life Sciences reported on November 17, 2026 topline results from the randomized, open-label Phase 3 REGAL trial of galinpepimut-S (GPS), an off-the-shelf vaccine made of four peptides derived from the WT1 protein, given as maintenance to adults with acute myeloid leukemia in second or later remission who could not undergo stem cell transplantation. In 126 patients randomized 1:1, median overall survival was 24.0 months with GPS versus 14.7 months with the investigator's choice of best available treatment (hazard ratio 0.59, p=0.035), and treatment-related side effects were mostly mild to moderate, mainly injection-site reactions. The results are company-reported, have not yet been peer-reviewed, and secondary endpoints are still being analysed; GPS is not approved, and the company plans to discuss a filing with the FDA, targeting the first half of 2027.

SELLAS press release · MSK announcement · ClinicalTrials.gov record

Setmelanotide: two-year TRANSCEND extension data in acquired hypothalamic obesity presented at ObesityWeek 2026

Rhythm Pharmaceuticals reported on November 16, 2026 two-year results from the open-label extension of the Phase 3 TRANSCEND trial of setmelanotide, a once-daily injected peptide that activates the melanocortin-4 receptor (MC4R), in people with acquired hypothalamic obesity. Of 125 participants who entered the extension, 81 had completed two years; mean BMI change was −18.8% in those treated continuously and −16.5% in those who switched from placebo after one year, with about −21% in adults in both groups. In the one-year placebo-controlled phase, published in the New England Journal of Medicine (120 participants aged 4 to 66), BMI changed by −16.5% with setmelanotide versus +3.3% with placebo, while serious adverse events occurred in 28% versus 8% and skin hyperpigmentation was the most common side effect. The two-year figures are company-reported conference data from an open-label extension without a control group and have not been peer-reviewed.

Rhythm press release · NEJM paper (Phase 3) · ClinicalTrials.gov record

SURMOUNT-ADOLESCENTS: once-weekly tirzepatide lowers BMI by 18.5% in teenagers with obesity in a Phase 3 trial (JAMA)

SURMOUNT-ADOLESCENTS, published in JAMA on November 15, 2026, randomised 160 adolescents aged 12 to under 18 with obesity, or overweight with at least one obesity-related complication, to once-weekly tirzepatide (109) or placebo (51) for 72 weeks at 31 centres in six countries, alongside a healthy-lifestyle programme. BMI fell by 18.5% with tirzepatide versus a 0.5% increase with placebo, and 79.6% of treated participants reduced their BMI by at least 5% versus 28.5% on placebo. Gastrointestinal side effects were the most common and mostly mild to moderate. Several authors are Eli Lilly employees, 72 weeks cannot show long-term effects on growth or what happens after stopping, and tirzepatide is currently approved for obesity only in adults.

JAMA paper · ClinicalTrials.gov record

STEP Young: once-weekly semaglutide lowers BMI in children aged 6 to under 12 with obesity in a Phase 3 trial (NEJM)

STEP Young, published in the New England Journal of Medicine on November 16, 2026, randomised 167 children aged 6 to under 12 with obesity to once-weekly semaglutide (112) or placebo (55) for 104 weeks, followed by a 7-week washout, with lifestyle counselling in both groups. At week 68, BMI changed by −13.5% with semaglutide versus +2.7% with placebo, and 38% of treated children were below the obesity threshold versus 2% on placebo; at week 104 the figures were −9.4% versus +8.4%. Adverse events occurred in 96% of children on semaglutide and 93% on placebo, with gastrointestinal events the most common and more frequent with semaglutide. The trial was funded by Novo Nordisk, longer follow-up is needed on growth and on what happens after stopping, and semaglutide is not approved for this age group.

NEJM paper · ClinicalTrials.gov record

Ribupatide GEMINI-1: once-weekly dual GIP/GLP-1 agonist produces up to 17.7% weight loss in a Phase 3 trial in China (JAMA)

GEMINI-1, published in JAMA on November 15, 2026, randomised 567 adults in China with overweight or obesity and no diabetes at 55 sites to once-weekly ribupatide (HRS9531) at 2, 4 or 6 mg or placebo, alongside lifestyle counselling, for 48 weeks. Average weight change was −10.7%, −16.4% and −17.7% with the three doses versus −1.4% with placebo, and 50.7%, 73.8% and 75.4% of participants lost at least 10% of their body weight versus 9.2% on placebo. Gastrointestinal side effects were the most common, reported by 48–63% of treated participants versus 23% on placebo, and were mostly mild to moderate and concentrated in the dose-escalation period. Participants were young (mean age about 34) and almost all Han Chinese, the trial was sponsored by Jiangsu Hengrui Pharmaceuticals, the authors note that 48 weeks may not capture the full effect, and ribupatide is not yet approved.

JAMA paper · ClinicalTrials.gov record

CagriSema REDEFINE 9: lower doses of the cagrilintide–semaglutide combination produce about 21% weight loss in a Phase 3b trial (The Lancet Diabetes & Endocrinology)

REDEFINE 9, published in The Lancet Diabetes & Endocrinology on November 14, 2026 and presented at ObesityWeek, randomised 309 adults with obesity, or overweight plus at least one weight-related condition and no diabetes, at 24 sites in Canada, Europe and the US to once-weekly CagriSema at 1.7 mg each or 1.0 mg each, or placebo, alongside lifestyle counselling for 68 weeks. If participants stayed on treatment, average weight change was −20.7% and −21.0% with the two doses versus −2.0% with placebo, and 95–96% of treated participants lost at least 5% of their body weight versus 33% on placebo; counting everyone regardless of whether they stopped treatment, the figures were −19.4% and −18.6% versus −4.6%. Adverse events, mostly mild to moderate and gastrointestinal, were reported by 99% and 95% of participants on the two doses versus 91% on placebo. The trial was relatively small, mostly female (77%), not designed to compare the two doses with each other, and funded by Novo Nordisk, and CagriSema has not yet been approved.

The Lancet Diabetes & Endocrinology paper · PubMed abstract

Week of 9 Nov 2026

CDC survey: about 1 in 10 US adults used a GLP-1 medication in the past year, and 44% of users changed how they took it (MMWR)

A CDC report published in Morbidity and Mortality Weekly Report on November 12, 2026 used Rapid Surveys System data from 8,118 adults, collected in July and August 2025, and found that 9.8% of US adults had taken a GLP-1 medication in the previous 12 months, including 47.4% of those reporting diabetes. Among users, 22.6% reported taking a compounded version and a further 8.8% did not know whether theirs was compounded, while 44% said they had modified their use from what was prescribed, most often by skipping doses (28%), with cost (38%) and availability (36%) the most common reasons. Modifications were more frequent among adults aged 18 to 39 than among those 65 and older (54% vs 30%) and among compounded-medication users (62% vs 36%). The data are self-reported from online panels with low response rates, so the findings describe patterns of use rather than effects on safety or effectiveness.

CDC MMWR report

Rare GLP-1 receptor gene variants linked to less weight loss on semaglutide but near-normal response to tirzepatide (Nature Metabolism)

A study published in Nature Metabolism on November 11, 2026 combined exome sequencing with health records from 13 North American health systems in the Helix Research Network and followed 13,725 adults who started semaglutide or tirzepatide for up to 12 months. People carrying rare damaging variants in the GLP1R gene lost less weight on semaglutide than matched non-carriers (2.4% vs 8.8%), while carriers on tirzepatide, which also acts on the GIP receptor, lost 13.3% vs 15.2%, a difference that was not statistically significant; rare GIPR variants were associated with near-normal responses. The carrier groups were very small (33 GLP1R carriers in total), the data come from routine care records, participants were mostly of European ancestry, and most authors are employees of Helix, so the findings need confirmation before any role in choosing treatment.

Nature Metabolism paper

Survodutide SYNCHRONIZE-CVOT: glucagon/GLP-1 dual agonist meets its cardiovascular safety goal in a 5,530-person Phase 3 trial (Lancet, AHA 2026)

Boehringer Ingelheim reported on November 9, 2026 that once-weekly survodutide, a glucagon/GLP-1 dual agonist licensed from Zealand Pharma, did not increase major cardiovascular events versus placebo in SYNCHRONIZE-CVOT, a double-blind Phase 3 trial in 5,530 adults with obesity or overweight and established cardiovascular disease, chronic kidney disease or multiple risk factors (5-point MACE HR 0.89, 95% CI 0.67-1.18, meeting non-inferiority). At 72 weeks, weight fell by up to 13.7% versus 2.0% with placebo, with lower systolic blood pressure and waist circumference, under an estimand that assumes continued treatment. The trial was designed to show safety, not cardiovascular benefit, and stopping treatment because of gastrointestinal side effects was common (19.3% and 20.8% on the two doses vs 1.9% on placebo). Boehringer says it is moving forward with global regulatory submissions in obesity.

Boehringer Ingelheim press release · Trial registration (NCT06077864)

FDA adds a class-wide warning about a rare optic nerve condition (NAION) to all GLP-1 receptor agonist labels

On November 9, 2026, the US FDA issued a Drug Safety Communication requiring the makers of all GLP-1 receptor agonists, including semaglutide, liraglutide, dulaglutide, tirzepatide and oral orforglipron, to add a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) to the Warnings and Precautions section of their labels. NAION can cause sudden, painless vision loss in one eye. In an FDA meta-analysis of 126 randomized trials with 134,253 participants, the rate was 6.4 cases per 100,000 person-years with GLP-1 drugs versus 3.8 with comparators, based on only 15 events in total; in a Sentinel cohort of adults with type 2 diabetes, risk was higher than with DPP-4 inhibitors (HR 1.43) but not significantly different from SGLT-2 inhibitors (HR 1.19). The FDA describes the risk as potential and the condition as rare, and found no mechanism in animal data.

FDA Drug Safety Communication

Semaglutide lowers heart filling pressures in obesity-related HFpEF: CAMEO-SEMA randomized trial (Nature Medicine)

A Mayo Clinic-led, double-blind, placebo-controlled trial randomized 81 adults with obesity and heart failure with preserved ejection fraction (HFpEF) to weekly semaglutide 2.4 mg or placebo for 52 weeks, with invasive heart pressure measurements at rest and during exercise. Pulmonary artery wedge pressure during low-intensity exercise, a direct measure of cardiac congestion, fell by 9.8 mmHg with semaglutide versus a 0.9 mmHg rise with placebo (difference −10.6 mmHg), resting pressure also fell, and 53.7% versus 7.4% of participants had normal pressures at both rest and exercise after one year; a companion MRI substudy reported improved left atrial function and heart filling. The trial was small and single-centre, its endpoints were pressure and imaging measures rather than hospitalizations or survival, and it cannot fully separate effects of weight loss from direct effects on the heart.

Nature Medicine paper · Cardiac MRI substudy · ClinicalTrials.gov

Week of 2 Nov 2026

Efinopegdutide (MK-6024): Phase 2b biopsy data show MASH resolution and fibrosis improvement at 52 weeks (AASLD)

Merck reported Phase 2b results for efinopegdutide, an investigational once-weekly GLP-1/glucagon receptor co-agonist licensed from Hanmi, in 381 adults with biopsy-confirmed MASH and stage F2–F3 fibrosis, presented as a late-breaking abstract at AASLD The Liver Meeting 2026. After 52 weeks, MASH resolution without fibrosis worsening reached 56%, 63% and 61% with the 4, 7 and 10 mg doses versus 13% with placebo, and at least one-stage fibrosis improvement without MASH worsening was 43%, 52% and 34% versus 21%; an open-label semaglutide 2.4 mg arm reached 53% and 25% on those endpoints. Gastrointestinal side effects were the most common, and 11% of participants on 10 mg stopped treatment because of adverse events versus about 3–4% on the lower doses. These are conference-abstract figures that have not been peer-reviewed, the semaglutide arm was open-label with no disclosed head-to-head statistical comparison, and efinopegdutide is not approved for any use.

AASLD late-breaking session · ClinicalTrials.gov · AASLD abstract report (The Bio)

Bofanglutide GRADUAL-3: once-monthly dosing maintained weight loss after a year of treatment

Gan & Lee Pharmaceuticals reported topline results from GRADUAL-3, a Phase 3b study in Chinese adults with obesity or overweight who had completed 52 weeks of its GLP-1 receptor agonist bofanglutide given every two weeks. Participants were then randomized to once-monthly bofanglutide (24 mg or 48 mg) or placebo for 24 weeks: body weight changed by +0.41% and -0.12% on the two bofanglutide doses versus +8.52% on placebo, and improvements in waist circumference, blood pressure and lipids were maintained. Side effects were mainly mild to moderate gastrointestinal events, with no new safety signals reported. These are company-reported topline results in a Chinese population only, and full data have not yet been presented or peer-reviewed.

Gan & Lee press release

Tirzepatide vs semaglutide in adolescents and young adults with obesity: greater BMI reduction in a large US records study

An abstract published in Circulation for the American Heart Association's Scientific Sessions 2026 used US health records (Epic Cosmos) to compare people aged 12-25 with obesity who started injectable tirzepatide or semaglutide between November 2023 and December 2025. Over 12 months, tirzepatide was associated with a greater BMI reduction than semaglutide in both adolescents aged 12-17 (1.57 percentage points more) and young adults aged 18-25 (5.91 percentage points more), along with larger blood pressure reductions. Safety was broadly similar in adolescents, while in young adults tirzepatide was linked to more pancreas and gallbladder-related events and semaglutide to more vomiting. This is an observational conference abstract that has not been fully peer-reviewed, and only 291 adolescents used tirzepatide, so the results cannot prove cause and effect and longer-term safety and growth data are still needed.

Circulation abstract

GLP-1 medicines vs metformin in prediabetes: lower risk of type 2 diabetes and heart events in a large records study

A study to be presented at the American Heart Association's Scientific Sessions 2026 analysed health records of 256,492 adults with prediabetes and obesity (average age 52, 76% women) who took either a GLP-1 medicine (semaglutide, tirzepatide, liraglutide or dulaglutide) or metformin, followed for about three years on average. Compared with metformin, GLP-1 users were about 1.5 times more likely to return to normal blood sugar levels, had a 31% lower risk of developing type 2 diabetes and a 41% lower risk of death, along with fewer heart attacks, strokes and heart failure events. The findings are a preliminary conference abstract that has not been peer-reviewed; the study is observational, relied on diagnosis codes and prescription records, and grouped different GLP-1 medicines together, so it cannot prove cause and effect.

American Heart Association news release

Tirzepatide vs semaglutide in heart failure with preserved ejection fraction and type 2 diabetes: fewer heart failure hospitalizations in a large real-world study

Researchers analysed US insurance claims for 37,183 adults with heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes who started once-weekly tirzepatide or semaglutide between 2022 and 2025, using a design that mimics a randomised trial. Over a median of 5.1 months, people starting tirzepatide had a 20% lower rate of hospitalization for heart failure (19.7 vs 25.5 per 1,000 person-years), while death rates were similar in both groups. The study is observational with short follow-up, so it cannot prove that one drug causes better outcomes, and randomised head-to-head trials are still needed.

Study in Diabetes, Obesity and CardioMetabolic CARE

October 2026
Week of 26 Oct 2026

Compounded GLP-1s: JAMA study of Nebraska prescription records finds out-of-state dispensing and frequent vitamin B12 add-ins

Researchers from the University of Utah, Duke and Boston University used Nebraska's prescription monitoring data, which captures all dispensed prescriptions, to study compounded weight-loss drugs from 2018 to April 2026. Compounded semaglutide and tirzepatide appeared only from 2024, and all 10,711 compounded GLP-1 prescriptions were filled by out-of-state pharmacies, with 99.5% of compounded weight-loss prescriptions paid privately. About two in three compounded tirzepatide prescriptions contained a vitamin B12 analogue, a combination not found in any approved product. The data show what was dispensed, not the actual composition, purity or potency of the products or any health outcomes.

JAMA research letter · Medscape report

Acmopatide (CT-868): GLP-1/GIP agonist built for type 1 diabetes cuts weight and insulin dose in a Phase 2 trial published in Diabetes Care

Genentech researchers published a 16-week, randomized, double-blind, placebo-controlled Phase 2 trial of acmopatide, a once-daily injected GLP-1/GIP receptor agonist, in 111 adults with type 1 diabetes and overweight or obesity. Body weight fell by 3.3% to 6.7% across the three doses, compared with a 0.3% gain on placebo, and the two higher doses lowered total daily insulin use. The improvement in HbA1c over placebo was modest and nominally significant only at the middle dose (0.3 percentage points). Side effects were mainly gastrointestinal and there were no cases of diabetic ketoacidosis or severe hypoglycaemia, but the trial was small and short, so larger and longer studies are needed.

Diabetes Care paper · Trial registration

US HHS issues enforcement discretion policy for compounding six peptides, including BPC-157 and TB-500

The US Department of Health and Human Services has filed a notice, scheduled for Federal Register publication on October 30, announcing an interim policy under which it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound products from six peptide bulk substances: BPC-157, TB-500, MOTS-c, Semax, KPV and Epitalon. The policy applies only while FDA works on the 503A bulks list through rulemaking, and it comes with conditions, including a patient-specific prescription, single-ingredient products, ingredients from FDA-registered manufacturers with full certificates of analysis, permitted routes of administration for each peptide, and reporting of serious adverse events to FDA. These peptides remain unapproved by FDA, their human safety and efficacy data are limited, FDA's drug center had previously recommended against listing them, and HHS says it may revisit the policy if safety or quality problems arise. The policy applies to US compounding only, and public comments are open for two weeks after publication.

Federal Register notice · HHS policy document

Retatrutide beats Ozempic 2 mg on blood sugar and weight in first head-to-head Phase 3 trial in type 2 diabetes

Eli Lilly has reported topline results from TRANSCEND-T2D-2, an 80-week, open-label Phase 3 trial comparing its investigational once-weekly retatrutide, a peptide that activates the GIP, GLP-1 and glucagon receptors, with semaglutide (Ozempic) 2 mg in 1,298 adults with type 2 diabetes not controlled on metformin, with or without an SGLT2 inhibitor. Both retatrutide doses (9 mg and 12 mg) lowered A1C by 2.2 percentage points versus 1.8 with Ozempic, from an average baseline of 8.3%, and body weight fell by 19.5% and 20.9% versus 9.4%. Gastrointestinal side effects were the most common, and 4.8% and 7.9% of retatrutide participants stopped treatment because of adverse events versus 2.7% on Ozempic. These are company-reported topline results using the efficacy estimand, not yet peer-reviewed, and retatrutide is not approved for any use; Lilly plans to file with the FDA in early 2027.

Lilly press release · Trial record

Camupepimut (ELI-002 7P): KRAS peptide vaccine misses primary endpoint in Phase 2 pancreatic cancer trial, with subgroup signals published in Nature Medicine

Elicio Therapeutics reported full results of the randomized Phase 2 AMPLIFY-7P trial of camupepimut, a vaccine made of seven lymph-node-targeted mutant KRAS peptides, at ESMO 2026 and in Nature Medicine. In 144 people with KRAS-mutated pancreatic cancer who had completed surgery and standard therapy, disease-free survival was not significantly better than observation (median 23.8 vs 21.2 months; HR 0.85). Prespecified subgroup analyses pointed to larger effects, for example in patients without circulating tumour DNA at baseline (HR 0.51), and grade 3 or higher adverse events occurred in 10.4% of vaccinated patients versus 14.6% under observation. The trial was open-label, the subgroup p-values are nominal and the arms were imbalanced at baseline, so these signals need confirmation in the Phase 3 trial the company plans to discuss with the FDA.

Nature Medicine paper · Elicio press release

TransCon PTH (palopegteriparatide): pooled trial data show kidney function gains sustained up to five years in hypoparathyroidism

Ascendis Pharma presented a pooled analysis of its Phase 2 PaTH Forward and Phase 3 PaTHway trials of TransCon PTH (palopegteriparatide), a once-daily parathyroid hormone prodrug, at the American Society of Nephrology's Kidney Week 2026. Across 139 adults with hypoparathyroidism, estimated glomerular filtration rate (eGFR, a measure of kidney function) rose by an average of 9.6 mL/min/1.73 m² from a baseline of about 69 by week 52 and then stayed stable for up to about five years, while 24-hour urine calcium roughly halved. The company reported no new safety signals. This is a company-reported, post hoc analysis presented as a conference poster, and most of the follow-up came from open-label extension periods without a placebo comparison.

Ascendis press release

Retatrutide reduces sleep apnoea severity in two Phase 3 trials, with and without type 2 diabetes (NEJM)

The New England Journal of Medicine has published results from TRIUMPH-1-OSA and TRIUMPH-2-OSA, two placebo-controlled Phase 3 trials of Eli Lilly's investigational once-weekly retatrutide, a peptide that activates the GIP, GLP-1 and glucagon receptors, in adults with moderate-to-severe obstructive sleep apnoea and a BMI of at least 27. After 80 weeks, the apnoea-hypopnoea index (breathing pauses per hour of sleep, about 56–59 at baseline) fell by about 22–24 more events per hour than with placebo at the two main doses in the 243 participants without diabetes, and by about 14–15 more events per hour in the 448 participants with type 2 diabetes; body weight fell by roughly 12–22% versus about 5% with placebo. Gastrointestinal side effects were the most common adverse events. The trials were funded by Lilly, the apnoea-hypopnoea index is a sleep-study measure rather than a clinical outcome, and retatrutide is not approved for any use.

NEJM paper

Week of 19 Oct 2026

Oral semaglutide lowers residual albuminuria in diabetic kidney disease in a small randomised trial (ASN Kidney Week 2026)

A single-centre, randomised, placebo-controlled study from Uzbekistan, presented as an abstract at ASN Kidney Week 2026 on 23 October, tested oral semaglutide in 92 people with diabetic kidney disease whose urine albumin stayed high (UACR 300–3000 mg/g) despite standard kidney-protective treatment, including RAS inhibitors, SGLT2 inhibitors and, in some cases, finerenone. After 16 weeks, albuminuria fell by 42% versus placebo with the higher of two tested doses and by 21% with the lower dose, alongside improvements in HbA1c, body weight and blood pressure; side effects were mostly mild to moderate gastrointestinal events. The study was small, short and run at one centre, the results are a conference abstract that has not yet been peer reviewed, and albuminuria is a surrogate marker, so the trial cannot show effects on kidney failure or other hard outcomes.

ASN Kidney Week abstract

Retatrutide: study of social media reports finds different self-reported side effects among people using unapproved versions (JAMA Network Open)

University of Pennsylvania researchers analysed 148,640 Reddit posts and comments about retatrutide, an investigational GIP/GLP-1/glucagon receptor agonist from Eli Lilly that is not approved anywhere, and identified 13,589 users describing their own use of non-approved products. Among the 7,823 users who reported at least one classifiable symptom (after excluding expected weight-loss and appetite-suppression effects), the most common were increased appetite, fatigue, increased energy, nausea, food cravings, insomnia and a raised heart rate, a pattern that differs from the mainly gastrointestinal side effects seen in Phase 2 trials. The study, published in JAMA Network Open, is a cross-sectional analysis of self-reports and cannot show that retatrutide caused these symptoms: the content, purity and dose of gray-market products could not be verified, many users may combine several peptides, and social media users are not representative. The authors describe the findings as hypothesis-generating and a signal for further safety monitoring.

JAMA Network Open study · Penn Engineering news

CagriSema: post hoc REDEFINE 1 analyses report about 25% average weight loss in women, across menopause stages

Novo Nordisk presented two post hoc analyses of the Phase 3 REDEFINE 1 trial of CagriSema (cagrilintide plus semaglutide, once weekly) at The Menopause Society 2026 Annual Meeting on 20 October 2026. Among 2,309 women with obesity or overweight, average weight loss at week 68 was 25.0% with CagriSema versus 3.0% with placebo, and in a separate analysis by menopausal stage it was 26.7% (premenopausal), 24.8% (perimenopausal) and 23.1% (postmenopausal), versus about 2% with placebo. These figures assume all participants stayed on treatment (efficacy estimand), menopausal status was assigned retrospectively, and the company describes the analyses as exploratory and hypothesis-generating. In REDEFINE 1 overall, 5.9% of participants stopped CagriSema because of side effects (mainly gastrointestinal) versus 3.5% on placebo; CagriSema is not yet approved, with a U.S. FDA decision expected in the fourth quarter of 2026.

Novo Nordisk press release · CNBC report

EloraTZP: Lilly registers Phase 3 AMPLIFY trials of its amylin–tirzepatide combination in obesity

Eli Lilly has registered two Phase 3 trials of EloraTZP, a co-formulation of the amylin agonist eloralintide with tirzepatide, on ClinicalTrials.gov (first posted 19 October 2026). AMPLIFY-1 plans to enrol about 2,115 adults with obesity (BMI 35 or higher) without type 2 diabetes and compare five EloraTZP doses with tirzepatide alone, eloralintide alone and placebo; AMPLIFY-2 plans about 1,000 adults with obesity or overweight and type 2 diabetes and compares EloraTZP with tirzepatide. Both trials use percent change in body weight at week 100 as the primary outcome. Neither trial is recruiting yet (estimated starts November–December 2026, primary completion around October 2029), so Phase 3 results are years away; in the earlier Phase 2b study, discontinuations due to side effects were more frequent with the combination than with tirzepatide alone.

AMPLIFY-1 (ClinicalTrials.gov) · AMPLIFY-2 (ClinicalTrials.gov)

GLP-1 receptor agonists linked to fewer psychiatric hospital admissions in schizophrenia with type 2 diabetes (The Lancet Psychiatry)

An observational cohort study in The Lancet Psychiatry used US electronic health records from 70,257 adults with schizophrenia and type 2 diabetes, followed for up to two years. People who started a GLP-1 receptor agonist had a lower risk of psychiatric hospitalisation than those who started no such medicine (weighted hazard ratio 0.76, about 24% lower), and also compared with people who started DPP-4 or SGLT2 inhibitors; psychiatric emergency department visits were lower too. Because this is an observational analysis, it shows an association rather than cause and effect, and the authors note possible residual confounding and selection bias. They say GLP-1 therapies should not be considered psychiatric treatments until randomised trials test this directly.

The Lancet Psychiatry · PubMed abstract

Week of 12 Oct 2026

Yuviwel (navepegritide): CHMP recommends EU approval for achondroplasia in children

On 16 October 2026, EMA's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending marketing authorisation for Yuviwel (navepegritide), Ascendis Pharma's once-weekly C-type natriuretic peptide (CNP) prodrug, for achondroplasia in children aged two years and older whose growth plates are not closed. The opinion follows review of three randomised, placebo-controlled trials plus up to three years of open-label extension data; pivotal ApproaCH results were published in JAMA Pediatrics. A final European Commission decision is expected in the fourth quarter of 2026 — a CHMP recommendation is not yet an EU approval. The medicine was already FDA-approved in February 2026 under the same brand name; if authorised, Ascendis plans a first EU launch in Germany in early 2027. Orphan designation status will be reassessed by EMA.

EMA CHMP highlights · Ascendis press release

TRIUMPH-2: retatrutide Phase 3 results in obesity with type 2 diabetes (The Lancet)

Full results of Eli Lilly's Phase 3 TRIUMPH-2 trial of retatrutide, an investigational once-weekly peptide that activates the GIP, GLP-1 and glucagon receptors, were published in The Lancet and presented at EASD 2026. In 1,152 adults with type 2 diabetes and obesity or overweight, average weight loss at 80 weeks was 12.7%, 19.1% and 20.8% with the 4, 9 and 12 mg doses, compared with 4.0% with placebo, and HbA1c fell by up to 1.6 percentage points from an average baseline of 7.7%. Gastrointestinal side effects such as diarrhoea, nausea and vomiting were more common than with placebo, and up to 11.6% of participants on retatrutide stopped treatment because of adverse events, versus 4.9% on placebo. The headline figures assume participants stayed on treatment (efficacy estimand), the trial was sponsored by the company, and retatrutide remains investigational; Lilly plans to submit it to the US FDA in early 2027.

The Lancet · PubMed · Lilly press release · ClinicalTrials.gov

Icotrokinra: oral IL-23 receptor-blocking peptide improves ulcerative colitis in Phase 2b ANTHEM-UC trial (NEJM)

Results of the Phase 2b ANTHEM-UC trial of Johnson & Johnson's icotrokinra, a once-daily oral peptide that blocks the interleukin-23 receptor, were published in the New England Journal of Medicine on 15 October 2026. Among 252 adults with moderately to severely active ulcerative colitis, all three doses beat placebo on the primary endpoint of clinical response at week 12 (63%, 58% and 55% for 400, 200 and 100 mg, versus 27% with placebo), and clinical remission was 30% with the 400 mg dose versus 11% with placebo. Adverse events through week 28 were reported at similar rates across the icotrokinra and placebo groups. This is a mid-stage, company-funded trial with a 12-week primary endpoint; remission at the 200 mg dose did not reach statistical significance, and longer, larger Phase 3 studies are needed before any approval in ulcerative colitis. Icotrokinra is already approved for plaque psoriasis.

NEJM · PubMed · ClinicalTrials.gov

RYZ101 (actinium-225 DOTATATE): Phase 3 ACTION-1 interim analysis meets progression-free survival goal in neuroendocrine tumors

Bristol Myers Squibb and its subsidiary RayzeBio announced on 12 October 2026 that the Phase 3 ACTION-1 trial met its primary endpoint at a planned interim analysis. RYZ101 links the somatostatin-receptor-targeting peptide DOTATATE to the alpha-emitting isotope actinium-225, and it improved progression-free survival compared with investigator's choice of standard care in patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors whose disease had progressed after lutetium-177-based therapy. The company describes these as the first Phase 3 results for an actinium-225 targeted radiopharmaceutical in any indication, with safety consistent with the known profile. These are company-reported topline results without published figures; the trial is open-label, overall survival is still being followed, detailed data are expected at a future medical meeting, and regulatory next steps will be discussed with the FDA.

Bristol Myers Squibb · OncLive · ClinicalTrials.gov

Oral semaglutide for obesity: U.S. prescriptions top 100,000 per month within two months of launch

An analysis by Johns Hopkins researchers, published online on 12 October 2026 in Annals of Internal Medicine, used national U.S. retail pharmacy data to track new prescriptions for the semaglutide pill for weight management after its January 2026 launch. It passed 100,000 new prescriptions per month within two months, compared with about four months for injectable tirzepatide and 20 months for injectable semaglutide, and injectable semaglutide prescriptions did not decline, suggesting the pill reached additional patients. The data were aggregated, so individual switching between drugs could not be tracked, off-label use could not be excluded, and cash payments and compounded products were not captured.

Annals of Internal Medicine · Medscape

RAY1225 (bilpatide): Zhongsheng Phase 3 REBUILDING-2 topline shows strong weight loss with biweekly dosing in China

Zhongsheng Pharmaceutical announced on 9 October 2026 company topline results from REBUILDING-2, a Phase 3 trial of RAY1225 (bilpatide), an investigational biweekly GLP-1/GIP dual agonist, in 641 Chinese adults with overweight or obesity at 50 centres. After 52 weeks, the 9 mg group lost 22.24% of body weight from baseline (placebo-adjusted 20.46%), with dose-dependent effects also at 3 mg and 6 mg; weight was still falling at week 52. These are preliminary company results from a China-only trial that have not been peer reviewed, and the notice did not disclose detailed adverse-event rates or discontinuations, stating only that safety was generally good with mostly gastrointestinal side effects; a type 2 diabetes Phase 3 trial is ongoing and China filing is planned.

Zhongsheng notice (Shanghai Securities News) · English summary (Fineline Cube)

HD1916: chemically synthesized semaglutide shows equivalent weight loss to Wegovy in Chinese Phase 3 trial

A Phase 3 trial published on 7 October 2026 in Diabetes, Obesity and Metabolism compared HD1916, a chemically synthesized version of semaglutide developed by CSPC, with the reference product Wegovy in 462 Chinese adults with obesity and without diabetes at 30 centres. After 44 weeks of once-weekly injections, mean weight loss was 13.1% with HD1916 and 14.4% with Wegovy, a difference within the prespecified equivalence margin, and treatment-emergent adverse events occurred in 86.5% and 89.2% of participants, mostly mild to moderate. The trial was open-label and limited to Chinese adults, and HD1916 was numerically slightly less effective.

Diabetes, Obesity and Metabolism · ClinicalTrials.gov

Week of 5 Oct 2026

TOGETHER-PsO: exploratory biomarker data for ixekizumab plus tirzepatide in psoriasis with obesity

Eli Lilly presented a prespecified exploratory analysis of its Phase 3b TOGETHER-PsO trial on 9 October 2026 at the Fall Clinical Dermatology Conference. The trial randomized 274 adults with moderate-to-severe plaque psoriasis and obesity or overweight to ixekizumab (Taltz) with or without tirzepatide (Zepbound); by week 36, the combination changed more blood proteins (482 vs 140) and genes (467 vs 16) than ixekizumab alone, including greater reductions in neutrophil-related inflammatory markers that accounted for part of the extra skin improvement. These are company-reported, exploratory biomarker findings from an open-label, assessor-blinded study and do not show clinical benefit on their own; the trial's main clinical results were reported earlier.

Lilly release · ClinicalTrials.gov

ZUPREME-2: petrelintide Phase 2 topline results in overweight or obesity with type 2 diabetes

Zealand Pharma reported on 7 October 2026 that its investigational once-weekly amylin analog petrelintide met the primary endpoint of the US Phase 2b ZUPREME-2 trial in 220 adults with overweight or obesity and type 2 diabetes. At week 28, mean weight loss was 7.4% to 9.2% across the three dose groups versus 2.0% with placebo, and placebo-adjusted HbA1c reductions ranged from 0.61 to 0.88 percentage points. Side effects were mainly mild gastrointestinal events during dose escalation, and 1.9% of participants on petrelintide stopped treatment because of gastrointestinal adverse events, compared with 1.7% on placebo. These are company-reported topline results from a 28-week trial that have not yet been presented in full or peer reviewed; the weight loss is lower than reported for GLP-1-based drugs in other trials, with no head-to-head comparison, and a Phase 3 program with Roche has started.

Zealand Pharma announcement · ClinicalTrials.gov

Efpeglenatide: South Korea approves Hanmi's GLP-1 receptor agonist for chronic weight management

South Korea's Ministry of Food and Drug Safety (MFDS) approved Hanmi Pharmaceutical's efpeglenatide (Epeoto Injector, 2 to 10 mg) on 7 October 2026 for chronic weight management in adults with obesity or overweight who do not have diabetes, as an add-on to a reduced-calorie diet and exercise. It is the first GLP-1-based obesity treatment developed in South Korea. In a Korean Phase 3 trial of 448 adults, mean body weight fell by 9.75% at week 40 versus 0.95% with placebo, and 49.5% of participants on efpeglenatide lost at least 10% of their body weight. These are company-reported interim week-40 results from a trial designed to run to week 64, the study enrolled only Korean participants, and the weight loss is numerically lower than in pivotal trials of semaglutide or tirzepatide, which were not compared head to head.

Approval report (Asia Business Daily) · Hanmi Phase 3 release

BGM0504: GLP-1/GIP dual agonist Phase 3 weight-management results in Chinese adults (EASD)

BrightGene presented 52-week Phase 3 results for BGM0504, an investigational once-weekly GLP-1/GIP dual receptor agonist injection, in 652 Chinese adults with overweight or obesity as a late-breaking oral presentation at EASD 2026 on 2 October. Mean weight loss was 14.3%, 17.3% and 19.2% with the 5, 10 and 15 mg doses versus 3.1% with placebo, and 48.9% of the 15 mg group lost at least 20% of their body weight; the company also reported improvements in waist circumference, blood pressure and uric acid. Gastrointestinal side effects were mostly mild to moderate, and 0.7% to 1.7% of participants stopped treatment because of adverse events. The trial enrolled only Chinese participants, a China marketing application was accepted in June 2026, and the figures come from a company congress release rather than a peer-reviewed paper.

BrightGene release (Chinese) · ClinicalTrials.gov

Week of 1 Oct 2026

Icotrokinra (ICOTYDE): two-year ICONIC-TOTAL data in plaque psoriasis at EADV

Johnson & Johnson presented two-year results from the Phase 3 ICONIC-TOTAL trial of icotrokinra, a once-daily oral peptide that blocks the IL-23 receptor, at EADV 2026; the trial enrolled 311 people (208 on icotrokinra, 103 on placebo) with plaque psoriasis affecting high-impact areas such as the scalp, genitals, hands or feet. Among patients treated with icotrokinra, the share with clear or almost clear skin (IGA 0/1) was 57% at week 16, 67% at week 24 and 70% at week 112, and the company reported no new safety signals. Placebo patients switched to icotrokinra at week 16, so there is no comparison group for the long-term results, and the data come from a company release and a conference presentation rather than a peer-reviewed paper. For context, the European Commission approved icotrokinra on 21 September 2026 for adults and adolescents (12 years and older, at least 40 kg) with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

J&J release · EU approval release · ClinicalTrials.gov

LIGHTEN: olatorepatide Phase 3 weight-management results in Chinese adults (EASD)

Hansoh Pharma reported Phase 3 LIGHTEN results for olatorepatide (HS-20094), an investigational once-weekly dual-biased GLP-1/GIP receptor agonist, in 604 Chinese adults with overweight or obesity; the data were presented as a late-breaking abstract at EASD 2026. At 48 weeks, mean weight loss was up to 19.3% with the 15 mg dose versus 2.7% with placebo, and waist circumference fell by up to 16.0 cm versus 3.6 cm (efficacy estimand, which assumes participants stayed on treatment). Across active arms the company reported nausea in 7.8% and vomiting in 4.9% of participants and said no one discontinued for treatment-related adverse events; the trial was China-only, a China NDA for adult weight management was accepted in June 2026, and Regeneron holds rights outside mainland China, Hong Kong and Macau. Figures come from a company congress release, not yet a peer-reviewed paper.

Hansoh / PR Newswire · ClinicalTrials.gov

SYNCHRONIZE-2: survodutide Phase 3 results in obesity with type 2 diabetes (NEJM)

Boehringer Ingelheim reported 76-week Phase 3 SYNCHRONIZE-2 results for survodutide, an investigational once-weekly glucagon/GLP-1 receptor dual agonist licensed from Zealand Pharma, in 755 adults with obesity or overweight and type 2 diabetes; the data were presented at EASD 2026 and published in NEJM. Mean weight loss was up to 13.1% versus 3.1% with placebo, and HbA1c fell by up to 1.21% versus 0.03% from a baseline of 7.4% (efficacy estimand, which assumes participants stayed on treatment). Gastrointestinal side effects such as nausea, vomiting, diarrhea and constipation were the most common, and 18% of participants on survodutide stopped treatment because of them versus 1.2% on placebo, mostly during dose escalation. Survodutide is not approved, and cardiovascular outcomes trial results are expected later this year.

Boehringer release · NEJM · ClinicalTrials.gov

EloraTZP: amylin–tirzepatide combination Phase 2b results in obesity with type 2 diabetes

Lilly reported 48-week Phase 2b results for EloraTZP, an investigational combination of the amylin agonist eloralintide and tirzepatide, in 367 adults with obesity or overweight and type 2 diabetes, presented at EASD 2026. At the highest dose combination, mean weight change was −23.3% versus −14.8% with tirzepatide 15 mg alone and −3.0% with placebo, and HbA1c fell by 2.9% versus 2.4% and 0.3% (efficacy estimand). Gastrointestinal side effects were more frequent with the combination, and discontinuations due to adverse events ranged from 10.8% to 27.0% versus 2.9% with tirzepatide alone. The data come from a company release and a congress presentation, not yet a peer-reviewed paper; Lilly plans Phase 3 trials of a co-formulated product by the end of 2026.

Lilly release · EASD (EurekAlert) · ClinicalTrials.gov

September 2026
Week of 29 Sep 2026

TRIUMPH-1: retatrutide Phase 3 obesity data in NEJM

Jastreboff et al. report an 80-week Phase 3 trial of once-weekly retatrutide (GIP / GLP-1 / glucagon agonist) in 2,339 adults with obesity without diabetes. Mean weight change at 12 mg was −25.0% versus −3.9% on placebo. GI events were the main adverse-event class. The molecule remains investigational.

NEJM DOI 10.1056/NEJMoa2604169 · Ars Technica summary

Lilly: retatrutide not FDA-approved; filing aimed Q1 2027

Eli Lilly’s public FAQ states retatrutide is not approved and is still in Phase 3 programmes (obesity, T2D, OA pain, OSA, CV/renal, MASLD). Company commentary around TRIUMPH-2/3 points to a US BLA package in Q1 2027 after CMC is complete — not a current pharmacy product.

Lilly FAQ · HCPLive TRIUMPH-2/3

Your cart 0

Your cart is empty

Prices are per vial, shown in lei and euro. Fan Courier delivers in Romania in 2–3 days.

Browse the catalogue
WhatsAppCustomer service — WhatsApp